Based on the provided case report, here is the complete RUCAM analysis.

### **SECTION A — HUMAN-READABLE FULL REPORT**

**1. Clinical Data Extraction**

*   **Patient:** 79-year-old female.
*   **History:** No prior liver or biliary disease. No history of blood transfusion.
*   **Drug Exposure:**
    *   **Suspect Drug:** Carbamazepine (200 mg daily).
    *   **Indication:** Facial neuralgia.
    *   **Start Date:** May 2, 1984.
    *   **Stop Date:** June 25, 1984 (Admission).
    *   **Concomitant Medications:** Vincamine (chronic use for years), Clobazepam (started May 2, 1984).
*   **Symptom Timeline:**
    *   **First Symptoms:** Itching on June 2, 1984.
    *   **Jaundice:** June 24, 1984.
    *   **Hospitalization:** June 25, 1984.
    *   **Time to Onset:** 31 days (itching), 53 days (jaundice).
*   **Laboratory Data (Admission, June 25):**
    *   **ALT:** 91 U (Normal 5-45). **2.02 x ULN**.
    *   **ALP:** 25 U (Normal 2-5). **5.00 x ULN**.
    *   **GGT:** 390 U (Normal 10-40).
    *   **Bilirubin:** 113 µmol/L.
    *   **Eosinophils:** 54% (Absolute count ~7,900/mm³ based on 14,700 WBC).
*   **Course:**
    *   All drugs interrupted on admission.
    *   Clinical manifestations resolved within 2 weeks.
    *   Labs returned to normal within 3 months.
    *   Rechallenge: Vincamine and Clobazepam were readministered without recurrence of injury. Carbamazepine was not readministered.
*   **Exclusions:**
    *   **Viral:** HBsAg, anti-HBs, anti-HBc, anti-HAV IgM absent.
    *   **Autoimmune:** ANA present (1:100); AMA, SMA, anti-ER absent.
    *   **Biliary:** Ultrasound normal; no evidence of obstruction over 1-year follow-up.
    *   **Parasitic:** Fascioliasis and echinococcosis serology negative.
    *   **Biopsy:** Acute cholangitis, ductular proliferation, inflammatory infiltrate (mononuclear/polymorphonuclear), no granuloma.

**2. Injury Pattern Analysis (R-Ratio)**

*   **Calculation:**
    *   ALT / ULN = 91 / 45 = **2.02**
    *   ALP / ULN = 25 / 5 = **5.00**
    *   R = 2.02 / 5.00 = **0.40**
*   **Interpretation:** R ≤ 2 indicates a **Cholestatic** liver injury pattern.
*   **Scoring Table:** The **Cholestatic/Mixed** RUCAM table will be applied.

**3. RUCAM Scoring Analysis**

*   **Time to Onset (+2):** The latency from the start of the drug (May 2) to the first symptom (itching, June 2) is 31 days. For cholestatic injury, a latency of 5–90 days scores +2.
*   **Course after Cessation (+2):** ALP is the primary marker for cholestatic injury. The text states liver function tests "returned to normal within three months" (approx. 90 days). This represents a decrease of ≥50% within 180 days.
*   **Risk Factors (+1):** The patient is 79 years old. Age >55 years scores +1. Alcohol use is not reported.
*   **Concomitant Drugs (0):** Clobazepam was started on the same day as Carbamazepine, which would typically suggest a compatible latency (-1). However, the text explicitly states that "Readministration of vincamine and clobazepam did not interfere with recovery," effectively ruling them out as causes. Therefore, no points are deducted.
*   **Non-Drug Causes Excluded (+1):**
    *   *Ruled out:* Biliary obstruction (Ultrasound), HAV, HBV, Autoimmune (AMA/SMA negative, biopsy consistent with drug-induced cholangitis), Parasites.
    *   *Not ruled out:* HCV and HEV (not available in 1987), Alcohol (not explicitly reported).
    *   *Scoring:* While the authors performed a comprehensive workup for the time, modern RUCAM standards require exclusion of HCV/HEV for a full score. Thus, this is scored as "Partial exclusion" (+1).
*   **Known Hepatotoxicity (+2):** Carbamazepine is a well-established hepatotoxin, known to cause granulomatous hepatitis and hepatocellular necrosis, and described in the text as causing "mild cholangitis" in previous reports.
*   **Rechallenge (0):** Carbamazepine was not readministered.

**4. Final Conclusion**

The total RUCAM score is **8**, which corresponds to a causality category of **Probable**. The case presents a classic cholestatic profile with strong temporal association, rapid resolution upon withdrawal, and exclusion of major mechanical and viral causes relevant to the era.

---

### **SECTION B — RUCAM SCORING TABLE**

| RUCAM Item | Score | Evidence |
| :--- | :--- | :--- |
| Time to onset | +2 | Start: May 2. Onset (itching): June 2. Latency: 31 days. (Range 5-90 days). |
| Course | +2 | "Liver function tests... returned to normal within three months." (Decrease ≥50% ALP within 180 days). |
| Risk factors | +1 | Age 79 years (>55). |
| Concomitant drugs | 0 | Vincamine and Clobazepam used. "Readministration of vincamine and clobazepam did not interfere with recovery" (Negative rechallenge rules them out). |
| Non-drug causes | +1 | Excluded: HAV, HBV, Biliary obstruction (US), Autoimmune (AMA/SMA neg). Missing: HCV, HEV (historical context). |
| Known hepatotoxicity | +2 | "Carbamazepine has been mainly implicated in two types of liver injury... mild cholangitis." |
| Rechallenge | 0 | "On the day of admission, all the drugs were interrupted." No rechallenge with Carbamazepine reported. |
| **Total** | **8** | **Category: Probable** |

---

### **SECTION C — MACHINE-READABLE JSON**

```json
{
  "injury_pattern": "cholestatic",
  "R_ratio": 0.4,
  "rucam_scores": {
    "time_to_onset": 2,
    "course": 2,
    "risk_factors": 1,
    "concomitant_drugs": 0,
    "other_causes_excluded": 1,
    "known_hepatotoxicity": 2,
    "rechallenge": 0
  },
  "total_score": 8,
  "category": "Probable"
}
```